Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab

Cited by papers we hold 6

• Lecanemab: Appropriate Use Recommendations · 2023
  No notice
• Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease · 2023
  No notice
• Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease · 2022
  No notice
• Aducanumab: Appropriate Use Recommendations Update · 2022
  No notice
• APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases · 2022
  No notice
• Aducanumab: Appropriate Use Recommendations · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.